Beoordelingsverslag van de commissaris aan de Raad van Bestuur – 26 juli 2022 July 26, 20220CommentsAuditor's Report to the Board of Directors (NL only) Read More
Beoordelingsverslag van de commissaris aan de Raad van Bestuur – 26 juli 2022 July 26, 20220CommentsAuditor's Report to the Board of Directors (NL only) Read More
Prospectus Nieuwe Aandelen – 19 juli 2022 July 19, 20220CommentsProspectus voor de toelating tot de handel op Euronext Brussels van maximal 15.651.259 nieuwe aandelen Read More
New Shares Prospectus – July 19, 2022 July 19, 20220CommentsProspectus for the admission to trading on Euronext Brussels of up to 15,651,259 new shares Read More
Speciaal verslag van de Raad van Bestuur – 18 juli 2022 July 18, 20220CommentsSpeciaal verslag van de Raad van Bestuur Read More
Board of Directors Special Report – July 18, 2022 July 18, 20220CommentsSpecial Report of the Board of Directors Read More
Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences July 11, 20220CommentsEN Read More
Tussentijdse halfjaarresultaten 30 juni 2022 June 30, 20220CommentsTussentijdse halfjaarresultaten 30 juni 2022 Read More
Interim Financial Report Half-year results as of June 30, 2022 June 30, 20220CommentsInterim Financial Report Half-year results as of June 30, 2022Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds June 30, 20220CommentsEN NL Read More
Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting June 13, 20220CommentsEN Read More
Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting June 3, 20220CommentsEN Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA May 31, 20220CommentsEN NL Read More
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting held on 24 May 2022 May 25, 20220CommentsEN NL Read More
Oxurion Announces Upcoming Preclinical Presentation on THR-149 at KININ2022 May 24, 20220CommentsEN Read More
Oxurion Announces Top-Line Results from Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME) May 9, 20220CommentsEN NL Read More
Oxurion Announces Results of the Extraordinary and Annual Shareholders’ Meetings of 3 May 2022 and Invitation to the Extraordinary Shareholders’ Meeting of 24 May 2022 May 6, 20220CommentsEN NL Read More
